effective over conventional methods
LAVAL, QC, Oct. 16 /PRNewswire/ - Laval-based provider of Central Laboratory and R&D Services to the biotechnology and pharmaceutical sectors, CIRION Clinical Trial Services Inc. has expanded its research capacity through the purchase of the latest technology.
Advertisement
CIRION's ongoing commitment to supporting its clients' projects through the latest technological advancements was highlighted at BioContact Quebec's 2008 Biopharmaceutical Partnership Symposium held in Quebec City October 1-3, 2008.
Advertisement
In a corporate overview, CIRION's Vice President of Business Development, Fraser Day, announced the acquisition of a new cutting edge technology platform to its extensive laboratory equipment. The state-of-the art Meso Scale SECTOR(TM) Imager 6000 reader is the newest member of the award-winning SECTOR(TM) Imager product line from Meso Scale Discovery headquartered in Gaithersburg, Maryland.
The Meso Scale platform utilizes electrochemiluminescent (ECL) detection to measure binding interactions between molecules, an integral part of the identification and development of protein-based drugs.
The ECL method offers a number of advantages over conventional immunoassay (ELISA, RIA) methods, such as high sensitivity and reliability, high throughput, lower sample volume requirements, greater speed of execution and the ability to measure multiple biomarkers in a single specimen simultaneously.
CIRION has been working with the previous generation of the Meso Scale platform and therefore, its clients can benefit from the expertise of trained scientists for the development of customized bioassays and solutions to clinical development challenges.
About CIRION
CIRION is a leading provider of Central Laboratory services for clinical studies and is well equipped to test drug candidates to accelerate clinical trials. The company offers a complete range of project management and logistical services, a broad portfolio of safety and specialized assays and development & validation services. CIRION has 12 years experience in developing assays and writing GLP procedures acceptable to regulatory agencies. The company is accredited from the College of American Pathologists (CAP) and the Center for Disease Control (CDC). For more information, please visit www.cirion.com.
SOURCE CIRION Clinical Trial Services Inc.
